Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme
Jun Agata(Medical University of South Carolina), Kazuaki Shimamoto(Yakult Central Institute), Masaya Hyakkoku(Sapporo Medical University), Haruki Sasaki(Sapporo Medical University), Hideaki Yoshida(Medical University of South Carolina), Shinya Taniguchi(Konan University), Nobuyuki Ura(Naruto, Tokushima Prefecture hospital), Yasuyuki Shinshi(Sapporo Medical University)
Cited by 135
Related Papers
Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)—Chapter 2
|Hypertension Research|2009|485
Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke
|JAMA Neurology|2019|214
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2018|174
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients
|Hypertension Research|2009|169
Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion
|American Journal of Physiology-Heart and Circulatory Physiology|2003|129